Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant iparomlimab + tuvonralimab with TCb for triple-negative breast cancer
ChiCTR2600133049Phase 2Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Sep 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab, tuvonralimab, paclitaxel, docetaxel and carboplatin in triple-negative breast cancer (TNBC), sponsored by First Hospital of China Medical University. Primary endpoints: Pathological complete response rate and Disease-free survival. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabpaclitaxeldocetaxelcarboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2600133049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133049.